SCHEMBL15380368

SCHEMBL15380368

O=[N+]([O-])c1cccc(F)c1-c1ccccc1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100A4 P26447 2/20 0.56
PTPRC P08575 1/20 0.56
MAPT P10636 3/20 0.50
KMT2A Q03164 2/20 0.50
RECQL P46063 1/20 0.50
MCL1 Q07820 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
TDP1 Q9NUW8 3/20 0.48
ALDH1A1 P00352 2/20 0.48
POLB P06746 2/20 0.47
APEX1 P27695 1/20 0.47
CASP6 P55212 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
MEN1 O00255 1/20 0.44
CSNK2A2 P19784 1/20 0.44
CSNK2B P67870 1/20 0.44
CSNK2A1 P68400 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluoride SCHEMBL27401565 0.93 S100A4 (0.56) S100A4PTPRCMAPTKMT2ARECQL
SCHEMBL27735808 0.86 S100A4 (0.50) S100A4PTPRCMAPTKMT2ARECQL
SCHEMBL27756532 0.86 S100A4 (0.50) S100A4PTPRCMAPTKMT2ARECQL
SCHEMBL11901648 0.86 S100A4 (0.50) S100A4PTPRCMAPTKMT2ARECQL
SCHEMBL30520118 0.84 S100A4 (0.47) S100A4PTPRCMAPTKMT2ARECQL
SCHEMBL2498443 0.83 S100A4 (0.50) S100A4PTPRCMAPTKMT2ARECQL
SCHEMBL13418991 0.82 TDP1 (0.59) S100A4PTPRCMAPTKMT2ATDP1
SCHEMBL12479506 0.81 TDP1 (0.48) S100A4PTPRCMAPTKMT2ARECQL
SCHEMBL28048984 0.81 TDP1 (0.53) S100A4PTPRCMAPTKMT2ARECQL
SCHEMBL19553980 0.81 S100A4 (0.45) S100A4PTPRCMAPTKMT2ARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10383880-B2 Carbazole-containing sulfonamides as cryptochrome modulators Synchronicity (US) 2019-08-20 US disclosed
US-10383880-B2 Carbazole-containing sulfonamides as cryptochrome modulators Synchronicity (US) 2019-08-20 US disclosed
EP-2855458-B1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS RESET THERAPEUTICS INC (US) 2018-08-08 EP disclosed
EP-2855458-B1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS RESET THERAPEUTICS INC (US) 2018-08-08 EP disclosed
US-20180071306-A1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2018-03-15 US disclosed
US-20180071306-A1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2018-03-15 US disclosed
US-20180071306-A1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2018-03-15 US disclosed
US-9775845-B2 Carbazole-containing sulfonamides as cryptochrome modulators RESET THERAPEUTICS, INC. (US) 2017-10-03 US disclosed
US-9775845-B2 Carbazole-containing sulfonamides as cryptochrome modulators RESET THERAPEUTICS, INC. (US) 2017-10-03 US disclosed
US-9775845-B2 Carbazole-containing sulfonamides as cryptochrome modulators RESET THERAPEUTICS, INC. (US) 2017-10-03 US disclosed
US-9265772-B2 Carbazole-containing sulfonamides as cryptochrome modulators RESET THERAPEUTICS, INC. (US) 2016-02-23 US disclosed
US-9265772-B2 Carbazole-containing sulfonamides as cryptochrome modulators RESET THERAPEUTICS, INC. (US) 2016-02-23 US disclosed
CN-104640856-A Carbazole-containing sulfonamides as cryptochrome modulators RESET THERAPEUTICS INC 2015-05-20 CN disclosed
EP-2855458-A1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS Reset Therapeutics, Inc. (US) 2015-04-08 EP disclosed
US-20130303524-A1 Carbazole-Containing Sulfonamides as Cryptochrome Modulators Synchronicity Pharma, Inc. 2013-11-14 US disclosed
US-20130303524-A1 Carbazole-Containing Sulfonamides as Cryptochrome Modulators Synchronicity Pharma, Inc. 2013-11-14 US disclosed
US-20130303524-A1 Carbazole-Containing Sulfonamides as Cryptochrome Modulators Synchronicity Pharma, Inc. 2013-11-14 US disclosed
WO-2013170186-A1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS RESET THERAPEUTICS, INC. (US) 2013-11-14 WO disclosed
CN-101374799-B Process for preparing substituted biphenyls BASF SE 2012-05-23 CN disclosed
CN-101374799-A Process for preparing substituted biphenyls BASF SE (DE) 2009-02-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303524-A1 Carbazole-Containing Sulfonamides as Cryptochrome Modulators CRY1, CRY2, CRYAB S100A4 1986/4885PTPRC 4319/4885MAPT 3089/4885
US-10383880-B2 Carbazole-containing sulfonamides as cryptochrome modulators CRY1, CRY2, CRYAB S100A4 2220/4885PTPRC 4338/4885MAPT 3146/4885
US-20180071306-A1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS CRY1, CRY2, CRYAB S100A4 2220/4885PTPRC 4338/4885MAPT 3146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.